This review evaluates interstitial lung disease (ILD) as an adverse effect in patients treated with antibody–drug conjugates (ADCs), covering the incidence, mechanisms, risk factors, and management strategies across ADC agents.
The review synthesizes evidence on ILD occurrence across multiple ADC therapies, highlighting it as a clinically significant and potentially fatal toxicity class effect, though specific pooled incidence rates or absolute numbers are not extractable from the provided metadata alone.
As a narrative review, it may be subject to publication bias and does not provide primary patient-level data; the breadth of ADC agents reviewed may limit depth of analysis for individual drugs.
Clinicians using ADCs should actively monitor for ILD throughout treatment; early recognition and prompt management—including dose modification or discontinuation—are critical to reducing ILD-related morbidity and mortality.
Explore related topics
